Lannett Company, Inc. today announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments.

Link:
Lannett enters into definitive agreement to purchase KU for $1.23 billion